Daniela Gallo

Dirigente Sanitario I livello - Head of Unit of Translational Medicine for Woman and Child Health

Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Cancer Biology Cancer Biology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Daniela Gallo is a Dirigente Sanitario I livello and the Head of Unit of Translational Medicine for Woman and Child Health at Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Italy. Her research focuses on high-grade serous ovarian cancer and includes recent studies on PARP1 levels, gene signatures for chemotherapy response, and the impact of hormone receptor expression. She is also involved in exploring biomarkers and therapeutic targets for related cancers, contributing to advancements in precision medicine.

Articles (10)

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (3)

Marianna BUTTARELLI

Assistant Professor (tenure track)

University of Rome Tor Vergata

ITALY

View details

Luciano Giaco'

Head of Bioinformatics

Policlinico Universitario Agostino Gemelli

ITALY

View details

Alfredo CESARIO

Chief Executive Officer

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Daniela Gallo

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer

Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients

What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study

Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application

Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study

Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibition

In search for biomarkers and potential drug targets for uterine serous endometrial cancer

Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go

KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer

Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer

Collaborators (3)

Marianna BUTTARELLI

Luciano Giaco'

Alfredo CESARIO

Make your next move.